Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39 by Michaud, Mickaël et al.
Subversion of the chemotherapy-induced
anticancer immune response
by the ecto-ATPase CD39
Mickaël Michaud,
1,2,3 Abdul Qader Sukkurwala,
1,2,3 Isabelle Martins,
1,2,3 Shensi Shen,
1,2,3 Laurence Zitvogel
2,4,5
and Guido Kroemer
1,2,6,7,8,9,*
1INSERM; U848; Villejuif, France;
2Institut Gustave Roussy; Villejuif, France;
3Université Paris Sud; Faculté de Médecine Paris XI; Le Kremlin Bicêtre, France;
4INSERM; U1015; Villejuif,
France;
5Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507; Villejuif, France;
6Metabolomics Platform; Institut Gustave Roussy; Villejuif, France;
7Centre de
Recherche des Cordeliers; Paris, France;
8Pôle de Biologie; Hôpital Européen Georges Pompidou; AP-HP; Paris, France;
9Université Paris Descartes; Paris 5; Paris, France
Keywords: anthracyclines, ATP release, immunogenic cell death, macroautophagy, oxaliplatin, cancer
The efficacy of antineoplastic chemotherapies with anthracyclines or oxaliplatin relies on the induction of immunogenic
cell death, thus provoking an anticancer immune response. Recently, we observed that overexpression of CD39, an ATP-
degrading enzyme expressed on the cell surface, abolishes the immunogenicity of cell death, thus rendering cancers
resistant against chemotherapy.
CD39 (also known as ectonucleoside tri-
phosphatediphosphohydrolase1,ENTPD1,
or nucleotide triphosphate diphosphohydro-
lase, NTPDase) is an enzyme that expresses
on thesurfaceof selectedcellularpopulations
such as endothelial cells and regulatory T
cells and that degrades extracellular ATP
to generate ADP and AMP. The latter
product may be converted by yet another
ecto-enzyme, CD73, to adenosine.
1 Extra-
cellular ATP, ADP, AMP and adenosine
act on different types of purinergic and
adinosinergic receptors to influence a
plethora of biological processes including
thrombocyte aggregation, nociception,
inflammation and immune responses.
Soluble CD39 has been shown to lower
extracellular ATP concentrations when
applied to animals, thereby reducing the
sequels of myocardial or cerebral ischemia.
2
CD39 is selectively expressed on the
surface of CD4
+CD25
+Foxp3
+ regulatory
T cells. In patients with head and neck
squamous cell carcinoma, particularly
those with active disease, the level of
expression of CD39 on regulatory T cells
is increased.
3 Similarly, in patients with
chronic lymphocytic leukemia (CLL),
circulating CD4
+ (regulatory?) T cells
overexpress CD39, and this parameter
may have a negative prognostic impact.
4
In mice, CD39 expression by regulatory
T cells has been shown to facilitate the
growth of intraportally injected cancer
cells in the liver, presumably through the
CD39-dependent inhibition of NK cells.
5
It has also been suggested that tumor cell-
derived exosomes may mediate immuno-
suppression by expressing CD39 and
CD73,
6 although formal evidence in favor
of this hypothesis is still elusive. Thus, the
available evidence suggests that CD39 is
immunosuppressive.
Anticancer chemotherapies are particu-
larly efficient when they elicit immuno-
genic cell death, which is a type of
apoptosis in which dying and dead cells
act as a therapeutic vaccine.
7 One of the
hallmarks of immunogenic cell death is
the secretion of ATP,
8 which occurs in
an active fashion as the cells expose
phosphatidylserine on their surface, before
they permeabilize their plasma mem-
branes.
9 The ATP release induced by
anthracyclines and oxaliplatin requires
the activation of caspases as well as the
pre-mortem activation of autophagy.
Inhibition of caspases or suppression of
autophagy abolishes ATP release; however
caspase activation alone or stimulation of
autophagy without cell death is insuffi-
cient to stimulate ATP release. Apparently
both processes must occur in a sequential
fashion (first autophagy, then caspase
activation) to allow for ATP to be released
into the microenvironment of dying
tumor cells.
9,10 Either the inhibition of
autophagy (by knockdown of essential
autophagy-relevant genes including Atg5
and Atg7) or the inhibition of caspases (by
transgenic expression of the baculovirus-
encoded caspase inhibitor p35) are suf-
ficient to abolish the immunogenicity of
cancer cell death induced by anthracy-
clines or oxaliplatin in vivo.
7,10
To assess the importance of the release
of ATP into the microenvironment of
dying tumor cells in a more direct fashion,
we expressed mouse CD39 on the surface
of MCA205 fibrosarcomas at the same
time as we generated a cell line transduced
by an empty vector (control cells). Cyto-
fluorometric analyses revealed that the vast
majority (. 90%) of the CD39-trans-
duced cells expressed CD39 at the surface,
while control cells lacked detectable CD39
expression.
10 We then assessed the effect of
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of cell death, using a combined in vitro/in
vivo approach. Control cells or CD39
+
MCA205 cells were treated with the
anthracycline mitoxanthrone in vitro to
induce approximately 70% of cell death.
Subsequently, the dying cells were ino-
culated subcutaneously into immuno-
competent C57Bl/6 mice. To assess the
capacity of these dying cell preparations to
vaccinate against tumor antigens, the mice
were inoculated one week later with live
parental MCA205 cells and tumor growth
was monitored. The vast majority of the
animals vaccinated with mitoxantrone-
treated control cells were protected against
the outgrowth of live MCA205 tumors. In
contrast, animals vaccinated with dying
CD39
+ MCA205 cells were not protected,
indicating that the expression of CD39
abolishes the immunogenicity of cell death
(Fig.1A).
Next, we assessed the impact of CD39
on chemotherapeutic responses. For this
we inoculated mice with control or
CD39
+ MCA205. Once the animals had
developed palpable tumors, we treated
them with systemic mitoxantrone-based
chemotherapy. Importantly, only control
tumors growing on immunocompetent
mice reduced their growth in response to
mitoxantrone. CD39
+ MCA205 cancers
growing on immunocompetent C57Bl/6
mice or any kind of tumor growing on
immunodeficient nu/nu mice failed to
reduce their growth rate after mitoxan-
trone treatment.
10 These results indicate
that CD39 expression is sufficient to
abolish the immune-dependent anticancer
effects of anthracyclines in vivo. This
immunosuppressive effect of CD39 can
be attributed to its ATP-degrading enzyme
because intratumoral injection of the
pharmacological ecto-ATPase inhibitor,
ARL67156, reestablished the efficacy of
anthracycline therapy, provided that this
treatment was applied to immunocompe-
tent hosts (Fig.1B).
The aforementioned results underscore
the essential contribution of extracellular
ATP to the immune response against
dying cells, presumably due to its capacity
to attract immune effectors including
dendritic cells (DC) into the proximity
of dying and dead cells
10 and to stimulate
inflammasome activation in DC.
8 In addi-
tion, they reveal the intriguing possibility
that CD39 expressed on regulatory T cells
that infiltrate the tumor bed might exert
similar immunosuppressive effects through
the depletion of ATP.
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Figure1. Effects of CD39 overexpression on the immunogenicity of cancer cell death.
(A) Vaccination experiments to evaluate immunogenic cell death. Control MCA205 fibrosarcoma
cells expressing vector only or MCA205 stably transduced with CD39 were killed by mitoxantrone
treatment in vitro. When 70 ± 10% of the cells stained with an Annexin V-FITC conjugate and/or
incorporated the vital dye propidium iodine, they were washed and injected subcutaneously into
the left flank of C57Bl/6 mice. One week later, the mice were challenged with live MCA205 cells
injected into the opposite flank. The absence of tumor growth after four weeks was then
interpreted as a sign of a protective anticancer immune response. (B) Immune-dependent
chemotherapeutic effects. Control or CD39-expressing cells were injected into C57Bl/6 wild type
(WT) or athymic nu/nu mice. The mice then received intraperitoneal injections of mitoxantrone
and/or intratumoral injections of the CD39 inhibitor ARL67156 (or PBS as vehicle controls) and
tumor growth was monitored for four weeks.
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